Press Releases

Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression
Date:2019-10-31

image.pngimage.png

image.png

image.png

image.png

image.png

image.png

image.png

image.png

image.png

image.pngimage.png

image.png

image.png

image.png

image.png

image.png

image.png

image.png


ShareTo:
Previous Page:
Green Valley Announces NMPA Approval Of Oligomannate For Mild To Moderate Alzheimer's Disease
Next Page:
Prof. Sangram Sisodia's Academic Visit to Green Valley Pharmaceuticals